“Navigating Routes to Commercial Success in Cell and Gene Therapy” discusses the unique challenges faced by companies developing and commercializing cell and gene therapies (CGTs). The paper highlights the significant potential of CGTs in treating previously incurable diseases and the need for a tailored approach to commercialization given the complexity of these therapies, high development costs, and regulatory hurdles. It provides an overview of the current market landscape and emerging trends in CGT development and commercialization, including the importance of real-world evidence, patient engagement, and pricing and reimbursement strategies. The paper also outlines best practices for successfully navigating the commercialization journey, including the importance of a cross-functional approach, strong data […]

While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to the therapy and supporting patients through the treatment journey. This is true for almost every specialty product, but it is especially important for cell and gene therapies, given the high cost and complexity of administering these innovative new therapies. On the surface, the commercialization process for cell and gene therapies may seem simple. However, many […]